“We were probably one of the lucky few that was able to go out last fall and have such a strong and successful IPO,” Bicara ...

Biotechs will need to be strategic to achieve “tariff-era success” as the sector enters an “America-first resurgence,” ...

When Australian biotech Telix Pharmaceuticals pulled a last-minute plug on its US public listing, it was yet another sign that the initial public offering (IPO) healthcare landscape was as ...

Omega Funds founder and managing director Otello Stampacchia isn’t afraid to tell it like he sees it.

More than three-quarters of private biotech investment tracked by BioPharma Dive between January and March was distributed ...

Dubbed the “IPO that wasn’t” by The Wall Street Journal, the firm traded 5.4 million shares at $12 each for six days before announcing that no shares would be issued. The company’s underwriters, ...

At the beginning of the year, pharma M&A was expected to rise and the biotech IPO market appeared steady. Now, the biotech space has been roiled by several abrupt changes stemming from new Trump ...

Brain Navi Biotechnology Co., Ltd. ("Brain Navi") has officially begun IPO counseling with First Securities Inc., marking a ...

Though biotech IPOs have been quiet since 2021, industry experts believe that falling interest rates and favorable conditions for investments could reopen the IPO window for companies seeking ...

Jyong Biotech Ltd. (Revived IPO) (MENS) is planning to raise $22 million in an initial public offering (IPO) on Wednesday, April 16th, IPO Scoop reports. The company plans to issue 2,700,000 ...